Green Cross stock advances after Phase 2 vaccine approval

Published on 09/30/2026 at 06:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Green Cross stock is advancing its GC4006A vaccine program after a September 11, 2026 Phase 2 approval. Second-quarter revenue fell 15.80 percent year over year.

Green Cross, KR7006280002, Illustration mit AI erstellt.

Green Cross (ISIN KR7006280002) stock is tied to a new clinical milestone after the company secured approval for a Phase 2 trial of its GC4006A COVID-19 mRNA vaccine. Edaily reported on September 11, 2026, that the first patients are expected to receive doses before year-end.

GC4006A moves into Phase 2

The trial will enroll healthy adults and older adults aged 19 to 85. GC Biopharma plans to compare GC4006A with an active control group, select the optimal dose and assess immunogenicity.

The company also plans to submit an application for a Phase 3 trial next year. Its stated target is domestic mRNA vaccine self-sufficiency by 2028, giving the program a longer development horizon beyond the immediate clinical milestone.

Quarterly revenue fell 15.80 percent

Second-quarter 2026 revenue was KRW 421.2 billion, down 15.80 percent from the same quarter of 2025, while operating profit was KRW 1.7 billion. ATS View reported the period figures and showed the comparison with the prior-year quarter.

Second-quarter net income was KRW 2.0 billion, compared with KRW 20.5 billion in the first quarter of 2026. The figures put the vaccine development story alongside a quarter in which sales contracted and operating profitability narrowed.

Stock remains below its yearly high

Green Cross was quoted at KRW 123,600 on the Korea Exchange on September 30, 2026 at 1:26 p.m. KST. The same quote set a 52-week range of KRW 105,900 to KRW 183,800 and indicated a market capitalization of KRW 1.4 trillion.

The identity is supported by MarketScreener, which lists GC Biopharma Corp. under ticker A006280 and ISIN KR7006280002. The company is listed on KOSPI and operates in pharmaceuticals, according to ATS View.